Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-19 in Moderate to Severe Active SLE
NCT06711146Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Meta10-19 in systemic lupus erythematosus (SLE), sponsored by Zhejiang University. Primary endpoints: Maximum Tolerated Dose at 35 days, Dose-Limiting Toxicities at 35 days and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
Meta10-19
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06711146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06711146.